Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

M. Gentile, F. Morabito, G. Del Poeta, F.R. Mauro, G. Reda, P. Sportoletti, L. Laurenti, M. Coscia, Y. Herishanu, A.G. Recchia, M. Varettoni, R. Murru, A. Chiarenza, A. Condoluci, R. Moia, D. Pietrasanta, G. Loseto, U. Consoli, I. Scortechini, F.M. RossiA. Zucchetto, V. Fraticelli, E. Vigna, C. Botta, G. Tripepi, G.D. Arrigo, A. Rago, I. Angeletti, A. Biagi, I. Del Giudice, R. Bomben, G.M. Rigolin, D. Rossi, F. Di Raimondo, G. Gaidano, A. Polliack, A. Cuneo, R. Foà, V. Gattei

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)235-238
Number of pages4
JournalLeukemia
Volume35
Issue number1
DOIs
Publication statusPublished - 2021

Keywords

  • beta 2 microglobulin
  • hemoglobin
  • ibrutinib
  • lactate dehydrogenase
  • adenine
  • immunological antineoplastic agent
  • piperidine derivative
  • protein kinase inhibitor
  • adult
  • age
  • aged
  • Article
  • biological functions
  • blood toxicity
  • cancer immunotherapy
  • cancer mortality
  • cancer prognosis
  • cancer staging
  • chromosome 17p
  • chromosome deletion
  • chronic lymphatic leukemia
  • clinical feature
  • cohort analysis
  • controlled study
  • cross validation
  • disease association
  • drug withdrawal
  • female
  • follow up
  • gender
  • gene
  • gene mutation
  • hemoglobin blood level
  • high risk patient
  • human
  • IGHV gene
  • intermediate risk patient
  • laboratory test
  • leukemia relapse
  • low risk patient
  • major clinical study
  • male
  • overall survival
  • prediction
  • priority journal
  • risk assessment
  • risk factor
  • salvage therapy
  • survival analysis
  • treatment duration
  • molecularly targeted therapy
  • mortality
  • prognosis
  • treatment outcome
  • Adenine
  • Antineoplastic Agents, Immunological
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Molecular Targeted Therapy
  • Piperidines
  • Prognosis
  • Protein Kinase Inhibitors
  • Treatment Outcome

Cite this